Liposomal irinotecan: Nursing considerations in an outpatient cancer center Journal Article


Authors: Kinsley, K.; Pritchett, W.
Article Title: Liposomal irinotecan: Nursing considerations in an outpatient cancer center
Abstract: Recent approaches in treating pancreatic adenocarcinoma, an aggressive disease with limited survival, include the use of liposomal irinotecan as an option when first-line therapy has failed. Liposomal irinotecan has been approved in combination with 5-fluorouracil and leucovorin for patients with metastatic pancreatic cancer. Liposomal irinotecan is a newer therapy requiring oncology nurses to obtain knowledge and skills for proper administrating, monitoring of hypersensitivity reactions during infusion, managing side effects, and providing patient education. Nursing considerations when administering this drug include infusion time, pre-medication, risk for hypersensitivity reactions and adverse events, and side effects. AT A GLANCE ☐ Newer treatment for metastatic pancreatic adenocarcinoma involves the use of liposomal irinotecan as second-line therapy. ☐ Liposomal irinotecan can improve drug delivery and reduce toxicity in metastatic pancreatic adenocarcinoma. ☐ Oncology nursing considerations for liposomal irinotecan involve chemotherapy administration, adverse events, and side effects. © 2018, Oncology Nursing Society. All rights reserved.
Keywords: patient education; liposomal irinotecan; metastatic pancreatic cancer
Journal Title: Clinical Journal of Oncology Nursing
Volume: 22
Issue: 2
ISSN: 1092-1095
Publisher: Oncology Nursing Society (ONS)  
Date Published: 2018-04-01
Start Page: 221
End Page: 224
Language: English
DOI: 10.1188/18.cjon.221-224
PROVIDER: scopus
PUBMED: 29547602
DOI/URL:
Notes: Article -- Export Date: 2 April 2018 -- Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors